Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab209899-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$109.90
|
|
|
Ab209899-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$509.90
|
|
|
Ab209899-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,399.90
|
|
|
Ab209899-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,299.90
|
|
Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | INSERM patent anti-DC-SIGN (anti-DC-SIGN) - Primary antibody, specific to CD209, Human IgG1 |
|---|---|
| Synonyms | C type lectin domain family 4 member L antibody | C-type lectin domain family 4 member L antibody | CD 209 antibody | CD209 antibody | CD209 antigen antibody | CD209 antigen-like protein A antibody | CD209 molecule antibody | CD209_HUMAN antibody | Cd209a |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response. Thought to mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. The |
| Host species | Human |
| Specificity | CD209 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
INSERM patent anti-DC-SIGN (anti-DC-SIGN) is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 150 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
INSERM patent anti-DC-SIGN (anti-DC-SIGN) (Ab209899) - ELISA
Immobilized Recombinant Human-DC- SIGN/CD209-his at 2.0 μg/mL can bind INSERM patent anti-DC-SIGN (anti-DC-SIGN) (Ab209899) with the EC₅₀ of 518.9 ng/mL.
INSERM patent anti-DC-SIGN (anti-DC-SIGN) (Ab209899) - SEC
The purity of INSERM patent anti-DC-SIGN (anti-DC-SIGN) (Ab209899) is more than 95% verified by HPLC.